Allogene Therapeutics Inc (NASDAQ: ALLO) is -30.52% lower on its value in year-to-date trading and has touched a low of $1.50 and a high of $5.78 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ALLO stock was last observed hovering at around $1.51 in the last trading session, with the day’s loss setting it -0.03%.
Currently trading at $1.48, the stock is -17.59% and -26.75% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.93 million and changing -1.99% at the moment leaves the stock -40.65% off its SMA200. ALLO registered -64.34% loss for a year compared to 6-month loss of -37.29%. The firm has a 50-day simple moving average (SMA 50) of $2.037 and a 200-day simple moving average (SMA200) of $2.50315.
The stock witnessed a -37.02% gain in the last 1 month and extending the period to 3 months gives it a -54.04%, and is -11.38% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.11% over the week and 7.96% over the month.
Allogene Therapeutics Inc (ALLO) has around 233 employees, a market worth around $310.31M and $0.04M in sales. Profit margin for the company is -659137.21%. Distance from 52-week low is -1.33% and -74.37% from its 52-week high. The company has generated returns on investments over the last 12 months (-51.64%).
with sales reaching $10.5k over the same period.The EPS is expected to grow by 36.25% this year, but quarterly earnings will post -68.42% year-over-year. Quarterly sales are estimated to shrink -50.00% in year-over-year returns.
Allogene Therapeutics Inc (ALLO) Top Institutional Holders
230.0 institutions hold shares in Allogene Therapeutics Inc (ALLO), with institutional investors hold 98.34% of the company’s shares. The shares outstanding are 209.50M, and float is at 140.82M with Short Float at 22.97%. Institutions hold 80.57% of the Float.
The top institutional shareholder in the company is FMR LLC with over 31.26 million shares valued at $72.83 million. The investor’s holdings represent 18.4816% of the ALLO Shares outstanding. As of 2024-06-30, the second largest holder is TPG GP A, LLC with 18.72 million shares valued at $43.61 million to account for 11.0663 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 16.45 million shares representing 9.7238% and valued at over $38.32 million, while VANGUARD GROUP INC holds 4.8458 of the shares totaling 8.2 million with a market value of $19.1 million.
Allogene Therapeutics Inc (ALLO) Insider Activity
The most recent transaction is an insider sale by Douglas Earl Martin, the company’s SVP, General Counsel. SEC filings show that Douglas Earl Martin sold 6,404 shares of the company’s common stock on Feb 03 ’25 at a price of $1.71 per share for a total of $10951.0. Following the sale, the insider now owns 0.59 million shares.
Allogene Therapeutics Inc disclosed in a document filed with the SEC on Feb 03 ’25 that Parker Geoffrey M. (CHIEF FINANCIAL OFFICER) sold a total of 4,361 shares of the company’s common stock. The trade occurred on Feb 03 ’25 and was made at $1.73 per share for $7545.0. Following the transaction, the insider now directly holds 1.3 million shares of the ALLO stock.
Still, SEC filings show that on Feb 03 ’25, MOORE TIMOTHY L. (Chief Technical Officer) disposed off 14,746 shares at an average price of $1.71 for $25216.0. The insider now directly holds 250,713 shares of Allogene Therapeutics Inc (ALLO).
